Aminex Therapeutics

About:

Aminex Therapeutics develops small molecule based cancer treatment solutions.

Website: http://www.aminextx.com

Twitter/X: aminextx

Description:

Aminex Therapeutics, Inc. is a drug development company focused on the discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies that enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex's vision is to make significant treatment contributions for a wide range of cancers and to ease the rising costs of cancer therapy.

Total Funding Amount:

$25.2M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Kirkland, Washington, United States

Founded Date:

2009-01-01

Contact Email:

markburns(AT)aminextherapeutics.com

Founders:

Mark Burns

Number of Employees:

1-10

Last Funding Date:

2021-08-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai